A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 589 participants.
Also called NCT01860729
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 589 participants
- Sponsor
- Registry
-
NCT01860729
-
- Other papers using this trial's data
- A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01860729. Randomized; double masking; primary purpose treatment. Start 2013-05-13 (actual); primary completion 2015-05-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Anacetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01860729- Content hash
a77418cbf8b202aa3ae3cdba441682cff2892b92c981e13d7949ca5b78229f3c